Stocktoria
HERON THERAPEUTICS, INC. /DE/ HRTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1987-08-26
HERON THERAPEUTICS, INC. /DE/ financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M | $88.6M | $146.0M | $77.5M | $30.8M | $1.3M |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | — | — | — | — | — | — |
| R&D expense | $12.4M | $16.7M | $39.1M | $82.7M | $130.8M | $174.5M | $167.4M | $140.0M | $138.6M | $103.1M |
| Operating income | -$2.5M | -$11.5M | -$110.6M | -$174.7M | -$217.8M | -$228.2M | -$210.7M | -$183.9M | -$194.6M | -$170.9M |
| Interest expense | — | — | $3.9M | $2.5M | $2.4M | $1.9M | $1.5M | $2.7M | $3.9M | $2.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M | -$220.7M | -$227.3M | -$204.7M | -$178.8M | -$197.5M | -$173.1M |
| EPS (diluted) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 | — | — | — | — | — |
| Operating cash flow | -$27.6M | -$22.5M | -$58.8M | -$146.9M | -$203.4M | -$184.8M | -$124.6M | -$191.8M | -$170.3M | -$134.1M |
| Free cash flow | -$27.9M | -$24.2M | -$60.3M | -$148.7M | -$206.4M | -$191.6M | -$131.7M | -$201.0M | -$172.9M | -$137.2M |
| Cash & equivalents | $28.6M | $25.8M | $28.7M | $15.4M | $90.5M | $105.1M | $71.9M | $31.8M | $144.6M | $13.4M |
| Inventory | $92.7M | $53.2M | $42.1M | $54.6M | $48.4M | $41.9M | $25.0M | $39.0M | $10.1M | $5.3M |
| Total assets | $255.9M | $233.1M | $222.5M | $251.0M | $305.7M | $353.6M | $512.8M | $462.2M | $234.3M | $67.5M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M | $117.1M | $108.9M | $92.0M | $103.2M | $88.7M |
| Shareholders' equity | $14.3M | -$33.7M | -$34.0M | $13.6M | $77.6M | $236.5M | $403.8M | $370.2M | $131.1M | -$21.3M |
Growth · year-over-year · Revenue CAGR 70.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +7.4% | +13.6% | +18.0% | +24.7% | -2.6% | -39.3% | +88.4% | +151.8% | +2305.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.